The Potential Harms of Human Gene Editing Using CRISPR-Cas9

First and foremost is the expectation of cures for blood disorders, lung diseases, cancers, and other maladies as clinician-scientists master various insertion, disruption, and deletion techniques. The Nuffield Council Genome Editing report affirms that "it is unlikely that, for the most part,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical chemistry (Baltimore, Md.) Md.), 2018-03, Vol.64 (3), p.489-491
1. Verfasser: Baylis, Françoise
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 491
container_issue 3
container_start_page 489
container_title Clinical chemistry (Baltimore, Md.)
container_volume 64
creator Baylis, Françoise
description First and foremost is the expectation of cures for blood disorders, lung diseases, cancers, and other maladies as clinician-scientists master various insertion, disruption, and deletion techniques. The Nuffield Council Genome Editing report affirms that "it is unlikely that, for the most part, therapies based on genome editing will raise distinctive issues for the handling of safety and efficacy considerations" ((6), p. 44). [...]in the discussion of genome editing in the context of biosecurity and dual use, the report confirms that "the UK research councils . . . recognise the possibility for misuse of research but express confidence in robust governance procedures for the research that they support and the applicability of existing regulatory frameworks" ((6), p. 103). In closing, while there is good reason to be enthusiastic about the prospect of developing safe and effective genetic treatments for persons with serious diseases, this enthusiasm must be tempered so as not to visit unnecessary harms on those who are invited to participate in research aimed at developing such therapies. [...]as progress is made in the realm of therapeutic somatic cell gene editing, we should be mindful of the implications for germ line gene editing and gene editing for enhancement purposes. First human embryosedited in U.S. MITTechnology Review; July 26, 2017. https://www.technolo gyreview.com/s/608350/first-human-embryos-editedin-us/?set=608352&utm_source=MIT+Technology+ Review&utm_campaign=0b6e65d565-The_Download& utm_medium=email&utm_term=0_997ed6f4720b6e65d565-154818457 (Accessed August 2017).
doi_str_mv 10.1373/clinchem.2017.278317
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2013194236</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2013194236</sourcerecordid><originalsourceid>FETCH-LOGICAL-p183t-6a97ffed1dd514cb6cd8406a4477590ea9af221c9896f14f472e8da6eb7523af3</originalsourceid><addsrcrecordid>eNotj11LwzAYhYMoWKf_wIuA15l5kzQfeCVlroOBY27XI2sS19Gms2n_vx16cw7PzXk4CD0DnQNX_LVq6lidfDtnFNScKc1B3aAMck6JziXcooxSaogBoe7RQ0rnCYXSMkNvu5PHm27wcahtg0vbtwl3AZdjayNe-ujxwtVDHb_xPl2z2K6-NltS2GQe0V2wTfJP_z1D-4_FrijJ-nO5Kt7X5AKaD0Rao0LwDpzLQVRHWTktqLRCKJUb6q2xgTGojDYygAhCMa-dlf6ocsZt4DP08rd76buf0afhcO7GPk7Kw3SYgxGMS_4LfaFKFg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2013194236</pqid></control><display><type>article</type><title>The Potential Harms of Human Gene Editing Using CRISPR-Cas9</title><source>Oxford University Press</source><creator>Baylis, Françoise</creator><creatorcontrib>Baylis, Françoise</creatorcontrib><description>First and foremost is the expectation of cures for blood disorders, lung diseases, cancers, and other maladies as clinician-scientists master various insertion, disruption, and deletion techniques. The Nuffield Council Genome Editing report affirms that "it is unlikely that, for the most part, therapies based on genome editing will raise distinctive issues for the handling of safety and efficacy considerations" ((6), p. 44). [...]in the discussion of genome editing in the context of biosecurity and dual use, the report confirms that "the UK research councils . . . recognise the possibility for misuse of research but express confidence in robust governance procedures for the research that they support and the applicability of existing regulatory frameworks" ((6), p. 103). In closing, while there is good reason to be enthusiastic about the prospect of developing safe and effective genetic treatments for persons with serious diseases, this enthusiasm must be tempered so as not to visit unnecessary harms on those who are invited to participate in research aimed at developing such therapies. [...]as progress is made in the realm of therapeutic somatic cell gene editing, we should be mindful of the implications for germ line gene editing and gene editing for enhancement purposes. First human embryosedited in U.S. MITTechnology Review; July 26, 2017. https://www.technolo gyreview.com/s/608350/first-human-embryos-editedin-us/?set=608352&amp;utm_source=MIT+Technology+ Review&amp;utm_campaign=0b6e65d565-The_Download&amp; utm_medium=email&amp;utm_term=0_997ed6f4720b6e65d565-154818457 (Accessed August 2017).</description><identifier>ISSN: 0009-9147</identifier><identifier>EISSN: 1530-8561</identifier><identifier>DOI: 10.1373/clinchem.2017.278317</identifier><language>eng</language><publisher>Washington: Oxford University Press</publisher><subject>Bioethics ; Biosecurity ; Cancer ; Clinical trials ; Councils ; CRISPR ; Design ; Ethics ; Gene therapy ; Genetic modification ; Genomes ; Hematological diseases ; Medicine ; Mutation ; Science</subject><ispartof>Clinical chemistry (Baltimore, Md.), 2018-03, Vol.64 (3), p.489-491</ispartof><rights>Copyright American Association for Clinical Chemistry Mar 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Baylis, Françoise</creatorcontrib><title>The Potential Harms of Human Gene Editing Using CRISPR-Cas9</title><title>Clinical chemistry (Baltimore, Md.)</title><description>First and foremost is the expectation of cures for blood disorders, lung diseases, cancers, and other maladies as clinician-scientists master various insertion, disruption, and deletion techniques. The Nuffield Council Genome Editing report affirms that "it is unlikely that, for the most part, therapies based on genome editing will raise distinctive issues for the handling of safety and efficacy considerations" ((6), p. 44). [...]in the discussion of genome editing in the context of biosecurity and dual use, the report confirms that "the UK research councils . . . recognise the possibility for misuse of research but express confidence in robust governance procedures for the research that they support and the applicability of existing regulatory frameworks" ((6), p. 103). In closing, while there is good reason to be enthusiastic about the prospect of developing safe and effective genetic treatments for persons with serious diseases, this enthusiasm must be tempered so as not to visit unnecessary harms on those who are invited to participate in research aimed at developing such therapies. [...]as progress is made in the realm of therapeutic somatic cell gene editing, we should be mindful of the implications for germ line gene editing and gene editing for enhancement purposes. First human embryosedited in U.S. MITTechnology Review; July 26, 2017. https://www.technolo gyreview.com/s/608350/first-human-embryos-editedin-us/?set=608352&amp;utm_source=MIT+Technology+ Review&amp;utm_campaign=0b6e65d565-The_Download&amp; utm_medium=email&amp;utm_term=0_997ed6f4720b6e65d565-154818457 (Accessed August 2017).</description><subject>Bioethics</subject><subject>Biosecurity</subject><subject>Cancer</subject><subject>Clinical trials</subject><subject>Councils</subject><subject>CRISPR</subject><subject>Design</subject><subject>Ethics</subject><subject>Gene therapy</subject><subject>Genetic modification</subject><subject>Genomes</subject><subject>Hematological diseases</subject><subject>Medicine</subject><subject>Mutation</subject><subject>Science</subject><issn>0009-9147</issn><issn>1530-8561</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNotj11LwzAYhYMoWKf_wIuA15l5kzQfeCVlroOBY27XI2sS19Gms2n_vx16cw7PzXk4CD0DnQNX_LVq6lidfDtnFNScKc1B3aAMck6JziXcooxSaogBoe7RQ0rnCYXSMkNvu5PHm27wcahtg0vbtwl3AZdjayNe-ujxwtVDHb_xPl2z2K6-NltS2GQe0V2wTfJP_z1D-4_FrijJ-nO5Kt7X5AKaD0Rao0LwDpzLQVRHWTktqLRCKJUb6q2xgTGojDYygAhCMa-dlf6ocsZt4DP08rd76buf0afhcO7GPk7Kw3SYgxGMS_4LfaFKFg</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Baylis, Françoise</creator><general>Oxford University Press</general><scope>3V.</scope><scope>4U-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TM</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>BKSAR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PCBAR</scope><scope>PDBOC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>S0X</scope></search><sort><creationdate>20180301</creationdate><title>The Potential Harms of Human Gene Editing Using CRISPR-Cas9</title><author>Baylis, Françoise</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p183t-6a97ffed1dd514cb6cd8406a4477590ea9af221c9896f14f472e8da6eb7523af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Bioethics</topic><topic>Biosecurity</topic><topic>Cancer</topic><topic>Clinical trials</topic><topic>Councils</topic><topic>CRISPR</topic><topic>Design</topic><topic>Ethics</topic><topic>Gene therapy</topic><topic>Genetic modification</topic><topic>Genomes</topic><topic>Hematological diseases</topic><topic>Medicine</topic><topic>Mutation</topic><topic>Science</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baylis, Françoise</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>University Readers</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Earth, Atmospheric &amp; Aquatic Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Earth, Atmospheric &amp; Aquatic Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>SIRS Editorial</collection><jtitle>Clinical chemistry (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baylis, Françoise</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Potential Harms of Human Gene Editing Using CRISPR-Cas9</atitle><jtitle>Clinical chemistry (Baltimore, Md.)</jtitle><date>2018-03-01</date><risdate>2018</risdate><volume>64</volume><issue>3</issue><spage>489</spage><epage>491</epage><pages>489-491</pages><issn>0009-9147</issn><eissn>1530-8561</eissn><abstract>First and foremost is the expectation of cures for blood disorders, lung diseases, cancers, and other maladies as clinician-scientists master various insertion, disruption, and deletion techniques. The Nuffield Council Genome Editing report affirms that "it is unlikely that, for the most part, therapies based on genome editing will raise distinctive issues for the handling of safety and efficacy considerations" ((6), p. 44). [...]in the discussion of genome editing in the context of biosecurity and dual use, the report confirms that "the UK research councils . . . recognise the possibility for misuse of research but express confidence in robust governance procedures for the research that they support and the applicability of existing regulatory frameworks" ((6), p. 103). In closing, while there is good reason to be enthusiastic about the prospect of developing safe and effective genetic treatments for persons with serious diseases, this enthusiasm must be tempered so as not to visit unnecessary harms on those who are invited to participate in research aimed at developing such therapies. [...]as progress is made in the realm of therapeutic somatic cell gene editing, we should be mindful of the implications for germ line gene editing and gene editing for enhancement purposes. First human embryosedited in U.S. MITTechnology Review; July 26, 2017. https://www.technolo gyreview.com/s/608350/first-human-embryos-editedin-us/?set=608352&amp;utm_source=MIT+Technology+ Review&amp;utm_campaign=0b6e65d565-The_Download&amp; utm_medium=email&amp;utm_term=0_997ed6f4720b6e65d565-154818457 (Accessed August 2017).</abstract><cop>Washington</cop><pub>Oxford University Press</pub><doi>10.1373/clinchem.2017.278317</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0009-9147
ispartof Clinical chemistry (Baltimore, Md.), 2018-03, Vol.64 (3), p.489-491
issn 0009-9147
1530-8561
language eng
recordid cdi_proquest_journals_2013194236
source Oxford University Press
subjects Bioethics
Biosecurity
Cancer
Clinical trials
Councils
CRISPR
Design
Ethics
Gene therapy
Genetic modification
Genomes
Hematological diseases
Medicine
Mutation
Science
title The Potential Harms of Human Gene Editing Using CRISPR-Cas9
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A55%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Potential%20Harms%20of%20Human%20Gene%20Editing%20Using%20CRISPR-Cas9&rft.jtitle=Clinical%20chemistry%20(Baltimore,%20Md.)&rft.au=Baylis,%20Fran%C3%A7oise&rft.date=2018-03-01&rft.volume=64&rft.issue=3&rft.spage=489&rft.epage=491&rft.pages=489-491&rft.issn=0009-9147&rft.eissn=1530-8561&rft_id=info:doi/10.1373/clinchem.2017.278317&rft_dat=%3Cproquest%3E2013194236%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2013194236&rft_id=info:pmid/&rfr_iscdi=true